Literature DB >> 19088030

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Maria L H Vlaming1, Zeliha Pala, Anita van Esch, Els Wagenaar, Olaf van Tellingen, Dirk R de Waart, Ronald P J Oude Elferink, Koen van de Wetering, Alfred H Schinkel.   

Abstract

PURPOSE: ATP-binding cassette sub-family C member 2 [ABCC2; multidrug resistance-associated protein 2 (MRP2)] and ABCC3 (MRP3) mediate the elimination of toxic compounds, such as drugs and carcinogens, and have a large overlap in substrate specificity. We investigated the roles of Abcc2 and Abcc3 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) in vivo. EXPERIMENTAL
DESIGN: Abcc2;Abcc3(-/-) mice were generated, characterized, and used to investigate possibly overlapping or complementary roles of Abcc2 and Abcc3 in the elimination of MTX and 7OH-MTX after i.v. administration of 50 mg/kg MTX.
RESULTS: Abcc2;Abcc3(-/-) mice were viable and fertile. In Abcc2(-/-) mice, the plasma area under the curve (AUCi.v.) for MTX was 2.0-fold increased compared with wild type, leading to 1.6-fold increased urinary excretion, which was not seen in Abcc2;Abcc3(-/-) mice. Biliary excretion of MTX was 3.7-fold reduced in Abcc2(-/-) but unchanged in Abcc2;Abcc3(-/-) mice. The plasma AUCi.v.s of 7OH-MTX were 6.0-fold and 4.3-fold increased in Abcc2(-/-) and Abcc2;Abcc3(-/-) mice, respectively, leading to increased urinary excretion. The biliary excretion of 7OH-MTX was 5.8-fold reduced in Abcc2(-/-) but unchanged in Abcc2;Abcc3(-/-) mice. 7OH-MTX accumulated substantially in the liver of Abcc2(-/-) and especially Abcc2;Abcc3(-/-) mice.
CONCLUSIONS: Abcc2 is important for (biliary) excretion of MTX and its toxic metabolite 7OH-MTX. When Abcc2 is absent, Abcc3 transports MTX and 7OH-MTX back from the liver into the circulation, leading to increased plasma levels and urinary excretion. Variation in ABCC2 and/or ABCC3 activity may therefore have profound effects on the elimination and severity of toxicity of MTX and 7OH-MTX after MTX treatment of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088030     DOI: 10.1158/1078-0432.CCR-08-1609

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Akira Kunimatsu; Masanori Nojima; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

3.  Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.

Authors:  Andrea N Edginton; Eric I Zimmerman; Aksana Vasilyeva; Sharyn D Baker; John C Panetta
Journal:  Cancer Chemother Pharmacol       Date:  2016-04-06       Impact factor: 3.333

4.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

5.  Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.

Authors:  Anika L Dzierlenga; John D Clarke; David M Klein; Tarun Anumol; Shane A Snyder; HongYu Li; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2016-05-27       Impact factor: 4.030

Review 6.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

7.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 8.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

9.  Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Authors:  K K Filipski; R H Mathijssen; T S Mikkelsen; A H Schinkel; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

10.  Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Authors:  Rhiannon N Hardwick; John D Clarke; April D Lake; Mark J Canet; Tarun Anumol; Stephanie M Street; Matthew D Merrell; Michael J Goedken; Shane A Snyder; Nathan J Cherrington
Journal:  Toxicol Sci       Date:  2014-07-31       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.